ArticlePublic health challenges2025
Preparing to Respond to the Next Pandemic: Impact of Key WHO IPC COVID-19 Response Products.
Article in Public health challenges, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparing to Respond to the Next Pandemic: Impact of Key WHO IPC COVID-19 Response Products.Public health challenges · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An outcomes/impact evaluation was undertaken (July 2023-April 2024) to evaluate the work of the World Health Organization (WHO) infection prevention and control (IPC) coronavirus disease (COVID-19) response team during the COVID-19 pandemic and to identify how to better prepare for the next pandemic. The evaluation used mixed methods, focusing on three pillars of the team's work: (1) interim guidance and guidelines; (2) OpenWHO IPC courses; and (3) risk communication and community engagement (RCCE) interventions. A literature review, interviews with WHO headquarters and regional staff, case studies, and multicountry surveys were undertaken. Of the national representatives surveyed, 97% reported that the guidelines impacted their work; overall 76% of Member States used RCCE interventions and products; and 99% of course participants used what they learned professionally or personally. Member States identified gaps relating to national contextualization, availability of feedback and monitoring mechanisms, and knowledge sharing. There is strong evidence of the impact, effectiveness, and use of this team's work in developing IPC COVID-19 guidelines and through courses developed and shared via OpenWHO; however, there is weaker evidence on the impact of RCCE products/interventions as a standalone activity. To be better prepared for the next pandemic, Member States and the WHO need to collectively identify how best to sustain the IPC gains and address the gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.